

Viable aerosolized *Mycobacterium tuberculosis* from sputum-positive and sputum-negative TB patients: Treatment effect and secular trends

Benjamin Patterson¹, Ryan Dinkele^{2,3}, Sophia Gessner^{2,3}, Anastasia Koch², Zeenat Hoosen⁴, Vanessa January⁴, Bryan Leonard⁴, Andrea McKerry⁴, Ronnett Seldon⁴, Andiswa Vazi⁴, Sabine Hermans¹, Frank Cobelens¹, Digby F. Warner^{2,3,5}, and Robin Wood^{3,4}

¹University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

²SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit & DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology, Faculty of Health Sciences, University of Cape Town, South Africa.

³Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.

⁴Desmond Tutu Health Foundation, University of Cape Town, South Africa.

⁵Wellcome Centre for Infectious Diseases Research in Africa, Faculty of Health Sciences, University of Cape Town, South Africa.

Abstract

Rationale: Knowledge of the potential for aerosol release of *Mycobacterium tuberculosis* (*Mtb*) during disease, treatment, recovery, and asymptomatic carriage is fundamental to understanding tuberculosis (TB) transmission.

Objectives: To quantify viable aerosolized *Mtb* from TB clinic attendees.

Methods: 102 presumptive TB patients from two informal settlements in Cape Town, South Africa, were classified by laboratory, radiological, and clinical features into three mutually exclusive groups: A. Sputum GeneXpert-positive TB (n=52), B. Sputum GeneXpert-negative TB (n=20), and C. TB not diagnosed (n=30). A respiratory aerosol sampling chamber was used to collect exhaled *Mtb* organisms over a 15-minute period at baseline, and at 2-weeks, 2-months and 6-months post initial presentation. Viable bacilli were enumerated based on incorporation of the fluorescent probe, DMN-trehalose.

Measures and Main Results: *Mtb* was isolated from 92%, 90% and 93% at baseline; 87%, 74%, 71% at 2 weeks; 53%, 47% and 46% at 2 months; and 32%, 25%, 22% at 6-months for groups A, B, and C, respectively. Median *Mtb* counts (ranges) reduced from baseline to 6 months from 10(1-38), 5(1-31), and 9(1-38) to 3(1-28), 4(3-18), and 2(1-14) for groups A, B, and C, respectively. TB symptoms resolved in all 3 groups.

Conclusions: Aerosolized *Mtb* was isolated from almost all TB patients at baseline and reduced during treatment. Small numbers of viable organisms remained in almost a fifth of patients completing 6-months' treatment. Aerosolized *Mtb* may be a useful metric for modifying standard TB therapy. Aerosolized *Mtb* in group C may reflect exacerbation of an existing infection or transient *Mtb*

infection not reaching a clinical threshold for TB diagnosis, consistent with recent models proposing cyclic subclinical disease states.

Introduction

Tuberculosis (TB) is uniquely characterised by *obligate* airborne transmission [1] with each new infection initiated following deposition of small diameter (<5µm) *Mycobacterium tuberculosis* (*Mtb*)-containing bioaerosols in the distal lung of a susceptible human host [2]. *Mtb* bioaerosols originate from infected individuals, so that proximity to the new (recipient) host is necessary for rebreathing of viable organisms to occur. The onward propagation of TB therefore depends on the processes of natural production, expulsion, and survival of airborne *Mtb* in small aerosols.

The lung has been described as an aerosol generator [3]: every exhaled breath contains a small volume of peripheral lung fluid released by a fluid film burst mechanism in terminal bronchioles [4]. Bioaerosol sampling captures this peripheral lung contribution, analogous to a non-invasive bronchoalveolar lavage. In contrast, sputum – which is produced in disease states – derives from mucin hyperproduction by goblet cells located in the upper conducting airways and confined to the trachea, bronchi, and larger bronchioles [5]. Bioaerosols might therefore represent a more suitable sample to identify *Mtb* in the lung periphery and to investigate individuals with no or minimal sputum production, including subclinical TB disease [6]. Furthermore, this sample has value both in demonstrating the presence of pathogen and indicating a quantitative transmission risk.

Given the low bacillary load, bioaerosol investigations depend on efficient capture and high sensitivity detection of viable *Mtb* organisms [7]. Previous studies have explored respiratory manoeuvres [8], collection devices [7], and the proximity of the participant to the collecting apparatus [9] to optimize collection of aerosolized *Mtb*. Groups employing cough aerosol [11] or facemask [12] sampling systems have achieved diagnostic sensitivities of 28% and 86%, respectively, in sputum-positive patients. Combining advanced aerosol sampling and fluorescence detection systems, we have previously reported a yield of viable *Mtb* of 95% in sputum GeneXpert-positive individuals [10].

Utilizing this technology, we aimed in the current study to capture and quantify viable *Mtb* from TB clinic attendees categorized into three mutually exclusive groups based on South African national TB treatment and diagnostic protocols [13]: laboratory-confirmed (GeneXpert-positive) TB (Group A), sputum GeneXpert-negative TB (Group B), and those not diagnosed with TB (Group C).

Methods and Materials

Study Design and Study Population

We recruited consecutive presumptive pulmonary TB patients over the age of 13 who self-presented to two community clinics serving two high-density, peri-urban residential areas south-west of Cape Town, South Africa.

A study protocol was published in advance [14] with the primary aim to compare proportions of *Mtb*-containing aerosols between sputum GeneXpert-positive (Group A) and sputum GeneXpert-negative

(Group B) TB patients. Assuming 20% bioaerosol positivity in Group B, and 100% positivity in Group A, a sample size of 250 was calculated to give 90% power to detect a difference between the groups [14]. As an interim analysis showed no difference in the proportions of positive aerosols between Groups A and B, the study was discontinued after recruitment of 102 patients. Ascertaining the prevalence proportion in Group C was an exploratory aim and the isolation of a high bioaerosol positive proportion in this group was unexpected. The detection of viable *Mtb* aerosols in the non-TB group, coupled with the concern that they might have unrecognized sputum GeneXpert-negative TB disease, necessitated longitudinal monitoring and sampling similar to the treated TB patients. Sampling intervals of baseline, 2-weeks, 2-months, and 6-months were applied to all three groups, A-C.

Sampling Protocol and Data Collection

A direct sampling protocol was developed as previously described [9]. Briefly, the respiratory aerosol sampling chamber (RASC) is a HEPA-filtered enclosure designed for investigation of respiratory bioaerosol emissions from a single individual. The RASC accommodates a Tyvek-suited participant seated and sampled via a metallic elliptical cone which comfortably accommodates each participant's head [9]. A unidirectional airflow is created by a high-flow (250L per minute) bespoke cyclone collector connected at the cone apex which extracts bioaerosol into a sterile phosphate-buffered saline (PBS) solution. Air enters the collector via a tangential nozzle which generates a liquid cyclone with particle inertia leading to deposition of bioaerosol from the airstream onto the wet wall. The exit airflow from the cone reaches a velocity of 12.5m per second, enabling full collection of all expiratory aerosols. Seated participants were directed by a study nurse to complete three 5-minute periods comprising 15 bronchiole burst manoeuvres (two successive deep exhalations), tidal breathing, and 15 coughs.

Ozone sterilization and empty RASC sampling were performed between participants to control for contamination.

At each visit, questionnaires were completed to determine the presence of symptoms including persistent cough (>2 weeks), recent weight loss, night sweats, loss of appetite, fever, haemoptysis, myalgias, and anosmia.

Fluorescence Detection of *Mtb*

The patient-derived bioaerosol output was captured in 5-10mL of PBS for each of the three respiratory manoeuvres. After centrifugation at $3000 \times g$ for 10 min, the pellet was resuspended in 200 μ L Middlebrook 7H9 medium and stained using the solvatochromic DMN-trehalose viability probe [15]. After overnight incubation in media containing DMN-trehalose, washed samples were added to a nanowell device [16]. The devices were sealed with adhesive film and centrifuged prior to visualization of the entire array by fluorescence microscopy. Detection and enumeration of

fluorescent bacilli was based on DMN-trehalose incorporation patterns and differential bacterial cellular morphology (cell length and width) by 5 microscopists, each blinded to participants and controls.

Confirmation of *Mtb* Detection

To confirm specificity of *Mtb* detection using the DMN-trehalose probe, conventional *Mtb* identification methods were employed. Alternative assays could not be sequentially applied post DMN-trehalose staining and the paucibacillary nature of the specimen precluded splitting of the sample. Therefore, for subsets of patient visits, additional bioaerosol sampling was performed in parallel to produce a second sample for investigation by auramine-O staining and DNA analysis using a droplet digital PCR-based technique and, where biomass allowed, whole-genome sequencing of extracted *Mtb* genomic DNA, as described below.

Auramine-O Staining

After overnight incubation in 200 μ L Middlebrook 7H9 medium, the pellet was smeared on a slide and microscopy was performed using Auramine-O fluorescent stain in accordance with the MGIT procedure manual [17]. *Mtb* H37Ra smears were prepared as positive controls for the staining technique.

Droplet Digital (dd) PCR of *Mtb* RD9

Mtb genomic DNA was extracted using an in-house lysis buffer with subsequent pelleting of DNA by centrifugation at 9000 \times g for 10 min, discarding of supernatant, and resuspension in 20 μ L Tris-EDTA (10 mM Tris, 1 mM EDTA, pH 8.0). The primer/probe combinations and reaction conditions for *Mtb* RD9-specific ddPCR have been described previously [4]. Serial dilutions of known concentrations of purified *Mtb* H37Rv genomic DNA were included as positive internal controls for ddPCR, and nuclease-free water was included as a negative control. Data generated from the ddPCR reactions were analyzed with the Umbrella pipeline [18] using only wells for which a minimum 10,000 droplets were detected.

***Mtb* Whole-Genome Sequencing**

Whole-genome sequencing (WGS) was performed on parallel samples following 50-day incubation at 37°C in 200 μ L Middlebrook 7H9-OADC growth medium to increase biomass of primary collections for DNA extraction. Sequencing libraries were prepared using the Nextera kit and WGS data were analyzed using previously described methods [20].

Statistical Analyses

The bioaerosol positivity proportions of groups A, B, and C were compared using Fisher's exact test and *Mtb* numbers with Wilcoxon rank sum tests. No correction was made for multiple comparisons.

Multivariable logistical regression analysis explored the impact of baseline demographic and clinical variables on the likelihood of initial *Mtb* bacillary count positivity. Further logistical regression analyses assessed whether bioaerosol clearance was associated with baseline variables. The three separate timepoints (2-weeks, 2-months, and 6-months) were investigated for clearance. For each analysis, data were dichotomised into count trajectories that cleared by that visit, defined as “no detectable DMN-trehalose *Mtb* bacilli”, and those that did not clear. All statistical analyses were performed using R Core Team (2021).

Ethics Statement

This study was approved by the Human Research Ethics Committee (HREC/REF: 529/2019) of the University of Cape Town. Written informed consent, including for publication of medical details, was obtained from all participants, and assent was obtained from under 18 year-olds.

Results

The study population of 102 TB clinic attendees underwent repeated bioaerosol sampling between 15th May 2020 and 27th May 2022. Of the participants sampled, 52 were sputum GeneXpert-positive (Group A); 20 were diagnosed as sputum GeneXpert-negative TB (Group B), 19 on the basis of chest radiography and 1 on clinical suspicion alone; and 30 were sputum GeneXpert-negative and not diagnosed with TB during 6-months of follow-up visits (Group C). One participant initially categorised as Group C was reclassified to Group B following radiographic TB diagnosis after the second visit. Notified TB patients (Groups A and B) received standard short-course therapy (2RHZE/4RH) for 6-months. Initial visit sampling was performed immediately before initiation of TB treatment. Eight participants in group C received short-course amoxicillin; no quinolones were prescribed.

Throughout the study, 16 participants were lost to follow-up, 4 relocated, 4 refused further sampling, 3 died, and 1 presenting with multidrug resistance was excluded. In total, there were 352 sampling visits with 72 participants completing all 4 visits (baseline, 2-weeks, 2-months, and 6-months post initial presentation).

Baseline characteristics varied between the groups (Table 1): Groups A and B had lower body mass indices (BMI) than Group C, while individuals in Group B were older and had a higher prevalence of HIV infection. Table 2 shows the percentage of patients in each group reporting each of the symptoms at the initial visit.

Microbiological Detection of Mtb in Bioaerosol

DMN-trehalose-positive (fluorescent) *Mtb* bacilli with characteristic morphological appearance were detected in all three groups. The prevalence proportions of *Mtb*-containing bioaerosols were 92%

(95% CI: 80-98), 90% (95% CI: 68-99), and 93% (95% CI: 77-99) for groups A, B, and C, respectively. Fisher's exact test showed no difference between the three groups (two-sided $p > 0.99$). Numerical counts for the entire 15-minute sampling period are shown in Figure 1. Sputum GeneXpert-positive (Group A) individuals trended towards producing greater *Mtb* numbers than the sputum GeneXpert-negative participants (Group B). Group C, comprising those without a TB diagnosis, produced similar *Mtb* counts to Group A but larger than Group B.

No *Mtb* bacilli were identified in any of the empty-RASC control samples which were run between participant samplings.

The three respiratory manoeuvres – bronchiole burst manoeuvre (BBM), tidal breathing (TiBr), and voluntary coughing (cough) were compared over all initial visits (See S1): all three showed numerically equivalent *Mtb* bioaerosol yields (BBM vs TiBr: $p = 0.25$; BBM vs cough: $p = 0.48$; TiBr vs cough: $p = 0.52$).

Longitudinal Bioaerosol Sampling

The time intervals for the longitudinal sampling were approximately >2-weeks (9-39 days; median 19 days), 2-months (49-111 days; median 61), and 6-months or end-of-treatment (EOT) (152-253 days; median 177) following initial sampling (see S2). The proportions of positive counts are shown in Figure 2. A progressive reduction was seen at each visit for each group, with proportions of 89%, 74%, 71% at 2-weeks; 52%, 44%, 48% at 2-months; and 32%, 20%, 22% at 6-months for groups A, B, and C, respectively. Numerical counts are shown in Figure 3. (S3 describes bacillary count trajectories)

Figure 4 demonstrates a reduction in the proportion of TB symptoms by group and visit.

To evaluate the possibility of a change in DMN-trehalose assay sensitivity over time, DMN-trehalose *Mtb* bacilli counts were plotted against calendar dates for each group and visit combination. The proportion of the variation explained by time was a median of 3% (R-squared range: <0.01 to 0.15).

DMN-trehalose assay specificity

Two parallel aerosol collections were investigated microscopically, one using conventional Auramine O ($n = 50$) staining, and a second with a ddPCR-based molecular assay targeting the *Mtb*-specific RD9 locus ($n = 40$), as reported previously [7]. Sequentially selected samples included both baseline and subsequent visits. Auramine-O staining was positive in 71% (42/50) of the samples tested. Whereas all (40/40; 100%) of the samples investigated by RD9 ddPCR were found to be positive.

Liquid Culture and Mtb Whole-Genome Sequencing

To ensure adequate *Mtb* biomass for WGS, 14 separate aerosol pellets from parallel samples were cultured in standard *Mtb* growth medium for 50 days. At the end of the incubation period, three

samples (one Group A, visit 1; two group C, visit 1) were selected for WGS based on inferred counts of >1000 *Mtb* genome copies by RD9-specific ddPCR. From these samples, 2,580,000-3,310,000 reads were analyzed and the presence of *Mtb* lineages 4.9 and 4.3 detected (Figure 5) according to the SNP

profile [20].

Predictors of DMN-trehalose positivity

Univariate analysis found that no baseline demographic or clinical variables (including age, sex, BMI, HIV status, sputum GeneXpert positivity, exposure to isoniazid preventive therapy, previous TB, smoking, or underlying lung disease) were associated with DMN-trehalose positivity at the initial visit (see S4). Similarly, there was no association with the presence of TB symptoms. A multivariable logistic regression model identified age to be associated with bioaerosol positivity with an odds ratio of 1.18 (95% CI: 1.05 to 1.4; $p=0.014$) for every year increase in age (see S5). There were no baseline predictors of *Mtb* bacillary clearance at any of the timepoints (see S6).

Discussion

This study demonstrates the combined use of the RASC and fluorescence microscopy to identify and monitor viable aerosolized *Mtb* in TB clinic attendees. The majority of bioaerosols captured at initial visit were *Mtb* positive, declining significantly over the 6 month study period. Median numbers of viable organisms isolated at each time point also declined, however not all individuals followed the trajectory of the group. Almost a third of sputum GeneXpert-positive patients remained *Mtb* bioaerosol positive at the 6-month point, albeit with a low median number of 3 *Mtb* bacilli – though one participant sample contained 28 organisms. Prospective studies will be required to confirm the utility of aerosolized *Mtb* for TB treatment monitoring, but it is notable that no baseline predictors of bioaerosol clearance were identified. Trajectories of aerosolized *Mtb* numbers during treatment may help distinguish those with early clearance – and, therefore, suitable for shortened therapy – from those who remain bioaerosol positive and require adherence support or further clinical surveillance.

Group A classification was based on objective microbiological results of sputum testing using GeneXpert. A high bioaerosol positivity in sputum GeneXpert-positive TB patients was therefore not unexpected and replicated the high sensitivity of detection among sputum GeneXpert-positive individuals reported in previous studies [8, 9]. Group B was more heterogeneous as assignment to this category depended on subjective assessment of clinical and radiological criteria. Group B participants were symptomatically similar to group A but with a higher prevalence of HIV infection and history of prior TB. The finding of *Mtb* organisms by non-invasive sampling of peripheral lung fluid in our study is compatible with the high diagnostic yield of bronchoalveolar lavage in sputum-negative TB [20] and consistent with previous evidence of transmission from this sub-group [22, 23].

The identification of viable *Mtb* in a subset of TB patients at EOT echoes previous findings of an FDG-PET/CT imaging study that tracked 99 HIV-negative patients through TB treatment and reported a range of outcomes with a proportion showing new FDG-avid lesions and ongoing inflammation [24]. In that work, *Mtb* mRNA transcripts were found in 37% of sputum and 100% of bronchoalveolar lavage (BAL) samples from EOT patients, implying presence of live organisms. A further study of non-sterilising cure found differentially culturable *Mtb* organisms in induced sputum and BAL after EOT, the presence of which correlated with FDG-PET/CT findings and subsequent clinical outcomes [25].

Another striking observation arising from our results is that even those participants not diagnosed with TB (*i.e.*, Group C) generated *Mtb* bioaerosols in an equivalent proportion and with counts similar to those observed for sputum GeneXpert-positive patients. Moreover, despite the absence of TB therapy or *Mtb*-active antibiotics, the Group C participants showed a decrease in proportion positivity and mycobacterial numbers over the 6-month period. These findings may indicate transient and spontaneously resolving *Mtb* infection, analogous to the oscillating sub-group originally proposed decades ago [26] and reiterated recently [29]. It remains uncertain, though, if this is due to a new TB exposure or to a perturbation of an existing, stable host-pathogen relationship. Group C patients did present with clinical symptoms, but these resolved in parallel with decreasing *Mtb* numbers. In accordance with the pre-planned pragmatic group allocation [14], no additional radiological investigations were carried out as part of this study and the exclusion of TB as likely diagnosis was made by TB clinicians without recourse to routine chest radiography. It is noteworthy, however, that only one individual initially allocated to Group C had ongoing symptoms which prompted a subsequent sputum GeneXpert-negative TB diagnosis and reassignment to Group B. DMN-trehalose uptake by bioaerosol-derived *Mtb* indicates that the captured bacilli are metabolically active but does not necessarily provide evidence that this specific phenotype has a role in TB transmission. However, unidentified *Mtb* transmitters, even at low levels, could account for a significant proportion of community exposure exacerbated by long infectious periods and lack of debilitating disease, as highlighted by a recent modelling study [27].

The finding of paucibacillary *Mtb* in bioaerosols of individuals without proven TB requires confirmation of the specificity of our assay. The DMN-trehalose probe requires mycolylation by the antigen-85 complex, a secreted protein of *Mycobacterium* spp. [28]. Studies of bacillary size, morphology, and staining characteristics have shown good agreement between patient samples and cultures of the laboratory strain, *Mtb* H37Rv [16]. DMN-trehalose staining has demonstrated characteristic bacillary morphological and staining phenotypes that reliably distinguish *Mtb* from non-mycobacteria [16]. Notably, a majority of DMN-trehalose-positive bioaerosols also stained with Auramine-O, a standard, widely utilized diagnostic of *Mtb* in sputum specimens. The DMN-trehalose stain identified organisms which decreased in parallel with the resolution of TB symptoms. All 40

participants with DMN-trehalose-positive bioaerosols yielded contemporaneous samples that were positive in our established ddPCR assay of the *Mtb*-specific RD9 locus. Furthermore, WGS of 3 cultured bioaerosols demonstrated the presence of distinct *Mtb* lineages.

Identification of transient *Mtb* bacilli in the bioaerosol of individuals with respiratory symptoms who are not diagnosed with TB despite clinical assessment is a novel finding which adds to the evidence of a broad TB disease spectrum. As noted above, it has been suggested that disease burden may cycle between states rather than follow a linear progression from infection to clinically apparent TB [26, 29]. These authors also speculated that intermittent periods of infectiousness occur, leading to unrecognized sources of community transmission. Individuals in Group C may represent these sources who, despite symptomatic presentation to a healthcare facility, remain clinically undiagnosed. The time of presentation conceivably corresponds to the peak in infectious bioaerosol production with the regression over time recapitulating the hypothesized cyclical oscillation. The occult presence of *Mtb* bacilli in peripheral lung fluid is also supported by a non-human primate model of *Mtb* infection in which bronchoscopic instillation of low-dose *Mtb* is used to recreate a mix of active TB disease and latent infection [30]. In that model, Lin *et al* identified a proportion of the latently infected cynomolgus macaques, described as percolators, in which bacilli were intermittently shed in bronchoalveolar lavage samples despite remaining disease-free [30]. Another source of evidence for disease regression comes from a recent systematic review of the pre-chemotherapy literature which used a Bayesian framework to make quantitative estimates of pathways between TB states, finding that 30% of subclinical, infectious individuals did not develop symptoms over 5-years while 16% regressed to minimal disease [31]. Other avenues of investigation have demonstrated host evidence of prolonged disease pre-diagnosis. These include FDG-PET/CT imaging studies which identified lesions consistent with bronchogenic reactivation of TB and active nodules in HIV-positive, asymptomatic individuals prior to development of symptoms [32], and transcriptomic signatures which predict TB progression in the 2-year period before symptomatic presentation in high-risk individuals [33]. Such studies highlight the complexity of the *Mtb* host-pathogen interaction, and the potential disconnect between symptoms and disease. Furthermore, data reported here and previous bioaerosol sampling studies demonstrate that tidal breathing alone can lead to emission of viable *Mtb* [10,12,34].

Limitations to this study include the pragmatic design [14], such that the patient groups were determined by the standard procedures and investigations of South African TB control program [13]. Therefore, the findings reflect a real-world healthcare scenario in South Africa and may lack the precision of a study with more thorough patient investigations – which might include both radiographical and immunological assays. Additionally, this study was performed in one of the highest TB burdened populations in the world so may not be generalisable to other lesser burdened populations. It is also worth noting that the study was undertaken between June 2020 and June 2022, a

period falling within the global Covid-19 pandemic with nationally mandated social interaction constraints and negative impacts on the health infrastructure including TB services.

Our knowledge of the TB host-pathogen relationship has been largely informed over the last 150 years by sputum-based studies. New technologies such as FDG-PET/CT imaging have changed our perspective of within-host TB pathology. Improved non-invasive bioaerosol collection devices such as facemask and RASC sampling have highlighted the potential utility of bioaerosols to give new insights into TB natural history, transmission, and treatment monitoring.

References

- [1] Roy, C. J., & Milton, D. K. (2004). Airborne Transmission of Communicable Infection — The Elusive Pathway. *N Engl J Med*, 350(17), 1710–1712. <https://doi.org/10.1056/NEJMp048051>
- [2] Cohen, S. B., Gern, B. H., Delahaye, J. L., Adams, K. N., Plumlee, C. R., Winkler, J. K., Sherman, D. R., Gerner, M. Y., & Urdahl, K. B. (2018). Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination. *Cell Host & Microbe*, 24(3), 439–446.e4. <https://doi.org/10.1016/j.chom.2018.08.001>
- [3] Gebhart J, et al. The human lung as aerosol particle generator. *J Aerosol Med*. 1988;1:196–197
- [4] Johnson, G. R., Morawska, L., Ristovski, Z. D., Hargreaves, M., Mengersen, K., Chao, C. Y. H., Wan, M. P., Li, Y., Xie, X., & Katoshevski, D. (2011). Modality of human expired aerosol size distributions. *Journal of Aerosol Science*, 42(12), 839–851. <https://doi.org/10.1016/j.jaerosci.2011.07.009>
- [5] Voynow, J. A., & Rubin, B. K. (2009). Mucins, Mucus, and Sputum. *Chest*, 135(2), 505–512. <https://doi.org/10.1378/chest.08-0412>
- [6] Fennelly, K. P., Acuna-Villaorduna, C., Jones-Lopez, E., Lindsley, W. G., & Milton, D. K. (2020). Microbial Aerosols: New Diagnostic Specimens for Pulmonary Infections. *Chest*, 157(3), 540–546. <https://doi.org/10.1016/j.chest.2019.10.012>
- [7] Patterson, B., Morrow, C., Singh, V., Moosa, A., Gqada, M., Woodward, J., Mizrahi, V., Bryden, W., Call, C., & Patel, S. (2017). Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients. *Gates Open Res*, 1, 11. <https://doi.org/10.12688/gatesopenres.12758.1>
- [8] Patterson, B., & Wood, R. (2019). Is cough really necessary for TB transmission? *Tuberculosis*, 117, 31–35. <https://doi.org/10.1016/j.tube.2019.05.003>
- [9] Patterson, B., Dinkele, R., Gessner, S., Morrow, C., Kamariza, M., Bertozzi, C. R., Kamholz, A., Bryden, W., Call, C., & Warner, D. F. (2020). Sensitivity optimisation of tuberculosis bioaerosol sampling. *PLoS ONE*, 15(9), e0238193. <https://doi.org/10.1371/journal.pone.0238193>
- [10] Patterson, B., Bryden, W., Call, C., McKerry, A., Leonard, B., Seldon, R., Gqada, M., Dinkele, R., Gessner, S., & Warner, D. F. (2021). Cough-independent production of viable Mycobacterium tuberculosis in bioaerosol. *Tuberculosis*, 126, 102038. <https://doi.org/10.1016/j.tube.2020.102038>
- [11] Fennelly, K. P., Jones-López, E. C., Ayakaka, I., Kim, S., Menyha, H., Kirenga, B., Muchwa, C., Joloba, M., Dryden-Peterson, S., & Reilly, N. (2012). Variability of Infectious Aerosols Produced during Coughing by Patients with Pulmonary Tuberculosis. *Am J Respir Crit Care Med*, 186(5), 450–457. <https://doi.org/10.1164/rccm.201203-0444oc>
- [12] Williams, C. M., Abdulwhhab, M., Birring, S. S., De Kock, E., Garton, N. J., Townsend, E., Pareek, M., Al-Taie, A., Pan, J., & Ganatra, R. (2020). Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies. *The Lancet Infectious Diseases*, 20(5), 607–617. [https://doi.org/10.1016/s1473-3099\(19\)30707-8](https://doi.org/10.1016/s1473-3099(19)30707-8)
- [13] http://www.kznhealth.gov.za/family/NTCP_Adult_TB_Guidelines_2014.pdf (Accessed 5th April 2022)
- [14] Patterson, B., Koch, A., Gessner, S., Dinkele, R., Gqada, M., Bryden, W., Cobelens, F., Little, F., Warner, D. F., & Wood, R. (2020). Bioaerosol sampling of patients with suspected pulmonary tuberculosis: a study protocol. *BMC Infect Dis*, 20(1). <https://doi.org/10.1186/s12879-020-05278-y>
- [15] Kamariza M, Shieh P, Ealand CS, Peters JS, Chu B, Rodriguez-Rivera FP, et al. Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe. *Sci Transl Med*. 2018;10(430). <https://doi.org/10.1126/scitranslmed.aam6310>.
- [16] Dinkele R, Gessner S, McKerry A, Leonard B, Seldon R, Koch AS, et al. (2021) Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols. *PLoS Pathog* 17(2): e1009262. <https://doi.org/10.1371/journal.ppat.1009262>
- [17] Siddiqi SH, Rüsç-Gerdes S. MGIT Procedure Manual for Bactec MGIT960 TB System. Geneva, Switzerland: Foundation for Innovative New Diagnostics; 2006
- [18] Jacobs BKM, Goetghebeur E, Vandesompele J, et al. Model-based classification for digital PCR: your umbrella for rain. *Anal Chem*. 2017;89:4461–7

- [19] Koch, A. S., Brites, D., Stucki, D., Evans, J. C., Seldon, R., Heekes, A., Mulder, N., Nicol, M., Oni, T., & Mizrahi, V. (2017). The Influence of HIV on the Evolution of Mycobacterium tuberculosis. *34*(7), 1654–1668. <https://doi.org/10.1093/molbev/msx107>
- [20] Coll, F., McNerney, R., Guerra-Assunção, J. A., Glynn, J. R., Perdigão, J., Viveiros, M., Portugal, I., Pain, A., Martin, N., & Clark, T. G. (2014). A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. *Nat Commun*, *5*(1). <https://doi.org/10.1038/ncomms5812>
- [21] de Gracia, J., Curull, V., Vidal, R., Riba, A., Orriols, R., Martin, N., & Morell, F. (1988). Diagnostic Value of Bronchoalveolar Lavage in Suspected Pulmonary Tuberculosis. *Chest*, *93*(2), 329–332. <https://doi.org/10.1378/chest.93.2.329>
- [22] Behr, M., Warren, S., Salamon, H., Hopewell, P., de Leon, A. P., Daley, C., & Small, P. (1999). Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. *The Lancet*, *353*(9151), 444–449. [https://doi.org/10.1016/s0140-6736\(98\)03406-0](https://doi.org/10.1016/s0140-6736(98)03406-0)
- [23] Xie, Y. L., Cronin, W. A., Proschan, M., Oatis, R., Cohn, S., Curry, S. R., Golub, J. E., Barry, C. E., & Dorman, S. E. (2018). *Transmission of Mycobacterium tuberculosis From Patients Who Are Nucleic Acid Amplification Test Negative*. *67*(11), 1653–1659. <https://doi.org/10.1093/cid/ciy365>
- [24] Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, III, Winter J, Walzl G, Lucas L, Spuy GV, Stanley K, Thiant L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S. 2016.
- [25] Beltran, C. G. G., Heunis, T., Gallant, J., Venter, R., du Plessis, N., Loxton, A. G., Trost, M., Winter, J., Malherbe, S. T., & Kana, B. D. (2020). Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy. *Front. Cell. Infect. Microbiol.*, *10*. <https://doi.org/10.3389/fcimb.2020.00443>
- [26] G.D. Gothi. Natural History of Tuberculosis, Wander-Tuberculosis Association of India Oration, Delivered on the occasion of the 32 nd National Conference on TB and Chest Diseases held at Trivandrum, November 1977
- [27] Issarow, C. M., Mulder, N., & Wood, R. (2018). Environmental and social factors impacting on epidemic and endemic tuberculosis: a modelling analysis. *R. Soc. Open Sci.*, *5*(1), 170726. <https://doi.org/10.1098/rsos.170726>
- [28] Kuo, C.-J., Bell, H., Hsieh, C.-L., Ptak, C. P., & Chang, Y.-F. (2012). Novel Mycobacteria Antigen 85 Complex Binding Motif on Fibronectin. *Journal of Biological Chemistry*, *287*(3), 1892–1902. <https://doi.org/10.1074/jbc.M111.298687>
- [29] Drain, P. K., Bajema, K. L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S. G., Ma, S., Meermeier, E., Lewinsohn, D. M., & Sherman, D. R. (2018). Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. *Clin Microbiol Rev*, *31*(4). <https://doi.org/10.1128/cmr.00021-18>
- [30] Lin, P. L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiosea, I., Capuano, S. V., Fuhrman, C., & Klein, E. (2009). Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model. *Infect Immun*, *77*(10), 4631–4642. <https://doi.org/10.1128/iai.00592-09>
- [31] Richards, A. S., Sossen, B., Emery, J. C., Horton, K. C., Heinsohn, T., Frascella, B., Balzarini, F., Oradini-Alacreu, A., Hacker, B., & Odone, A. (n.d.-b). *The natural history of TB disease-a synthesis of data to quantify progression and regression across the spectrum*. <https://doi.org/10.1101/2021.09.13.21263499>
- [32] Esmail, H., Lai, R. P., Lesosky, M., Wilkinson, K. A., Graham, C. M., Coussens, A. K., Oni, T., Warwick, J. M., Said-Hartley, Q., & Koegelenberg, C. F. (2016). Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. *Nat Med*, *22*(10), 1090–1093. <https://doi.org/10.1038/nm.4161>
- [33] Gupta, R. K., Turner, C. T., Venturini, C., Esmail, H., Rangaka, M. X., Copas, A., Lipman, M., Abubakar, I., & Noursadeghi, M. (2020). Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. *The Lancet Respiratory Medicine*, *8*(4), 395–406. [https://doi.org/10.1016/S2213-2600\(19\)30282-6](https://doi.org/10.1016/S2213-2600(19)30282-6)
- [34] Dinkele, R., Gessner, S., McKerry, A., Leonard, B., Leukes, J., Seldon, R., Warner, D. F., & Wood, R. (2022). *Aerosolization of Mycobacterium tuberculosis by tidal breathing*. <https://doi.org/10.1101/2021.10.17.464541>

Table 1. Characteristics of patients stratified by group: A) n=52 sputum GeneXpert-positive; B) n=20 sputum GeneXpert-negative TB; and C) n=30 non-TB diagnosis. Normally distributed continuous variables are reported as means with standard deviations in brackets. Categorical variables are reported as counts with percentages in brackets.

	A	B	C
n	52	20	30
Age (mean (SD))	33.6 (9.8)	45.0 (10.9)	39.6 (11.7)
Sex (%)	32 (61.5)	12 (60.0)	19 (63.3)
BMI (mean (SD))	19.9 (3.9)	20.6 (2.9)	23.9 (6.3)
HIV status (%)			
Negative	33 (63.5)	5 (25.0)	18 (60.0)
Positive	19 (36.5)	15 (75.0)	11 (36.7)
Unknown	0 (0.0)	0 (0.0)	1 (3.3)
On ARVs (%)			
Defaulted before the study	9 (50.0)	5 (35.7)	0 (0.0)
No	4 (22.2)	3 (21.4)	3 (27.3)
Yes	5 (27.8)	6 (42.9)	8 (72.7)
CD4 Count (median [IQR])	162.0 [95.0, 245.0]	143.5 [57.8, 213.5]	148.0 [86.0, 242.0]
On INH prophylaxis (%)			
Defaulted before the study	1 (2.2)	1 (5.3)	0 (0.0)
No	43 (95.6)	18 (94.7)	21 (91.3)
Yes	1 (2.2)	0 (0.0)	2 (8.7)
Previous TB (%)	17 (32.7)	13 (65.0)	15 (50.0)
Number of Previous TB Episodes (%)			
1	11 (61.1)	8 (66.7)	13 (86.7)
2	3 (16.7)	2 (16.7)	2 (13.3)
3	4 (22.2)	2 (16.7)	0 (0.0)
Pre-existing Lung Disease (%)	3 (5.9)	0 (0.0)	4 (13.3)
Smoking (%)	25 (51.0)	10 (52.6)	10 (33.3)

Table 2. Presenting symptoms at baseline for the three groups. Number of individuals reporting symptom given with percentage for the group in brackets.

	A	B	C
n	52	20	30
Persistent Cough (%)	45 (86.5)	12 (60.0)	19 (63.3)
Weight Loss (%)	46 (88.5)	16 (80.0)	20 (66.7)
Night Sweats (%)	38 (73.1)	8 (40.0)	12 (40.0)
Loss of Appetite (%)	28 (53.8)	4 (20.0)	6 (20.0)
Fever (%)	7 (13.5)	1 (5.0)	8 (26.7)
Haemoptysis (%)	5 (9.6)	0 (0.0)	2 (6.7)
Myalgias (%)	8 (15.4)	1 (5.0)	4 (13.3)
Anosmia (%)	1 (1.9)	1 (5.0)	0 (0.0)




Figure 1. Counts of putative *Mtb* bacilli at the first visit in advance of TB treatment. Groups A, B, and C are compared, with the thick bars representing median values. Wilcoxon rank sum tests p-values are shown for the three comparisons.




Figure 2. Proportion positivity of *Mtb* detection with longitudinal sampling. All visits where any visualised *Mtb* bacillus was counted in the sample were included in the numerator. The denominator is all visits yielding an interpretable sample. Owing to contamination of slides, 13 samples were uninterpretable; these are not included in the denominator of the prevalence proportions. The error bars represent the standard error of the mean.




Figure 3. Counts of putative *Mtb* bacilli with longitudinal sampling. The three panels show *Mtb* bacillary counts for groups A, B, and C varying against time from first sampling, with lines connecting the samples from the same patient at each successive visit.




Figure 4 Proportion of patients in each Group-Visit combination with symptoms determined by patient questionnaire.

Sample	Group	Visit	Mtb DNA copies	Genome Coverage	Mtb Lineage	Kraken Mapping
S1	C	1	38645	38.88	4.9	97
S2	A	1	24793	30.30	4.9	97
S3	C	1	1028	0.39	4.3	0.1
S4	C	4	89	0.06	ND	ND

ND = Not detected

Figure 5 Table shows sample characteristics and *Mtb* whole-genome sequencing results.